Reply to "GLP1RA versus SGLT2i tended to have more favorable ischemic outcomes including stroke?"

被引：0
|
作者：
Hwang, In-Chang [1 ,2 ]
Kim, Chee Hae [3 ]
机构：
[1] Seoul Natl Univ, Cardiovasc Ctr, Dept Internal Med, Bundang Hosp, Seongnam, Gyeonggi, South Korea
[2] Seoul Natl Univ, Div Cardiol, Bundang Hosp, Seongnam, Gyeonggi, South Korea
[3] Div Cardiol, Dept Internal Med, VHS Med Ctr, Seoul, South Korea
来源：
INTERNATIONAL JOURNAL OF CARDIOLOGY | 2022年 / 369卷
关键词：
D O I：
10.1016/j.ijcard.2022.08.047
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：12 / 12
页数：1
相关论文
共 50 条
  • [31] Initiation of SGLT2i Versus GLP1-RA and the Risk of Chronic Kidney Disease in Persons with Type 2 Diabetes Mellitus
    Jensen, Simon K.
    Heide-Jorgensen, Uffe
    Andersen, Ina T.
    Thomsen, Reimar W. W.
    Christiansen, Christian Fynbo
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 87 - 87
  • [32] SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
    Anson, Matthew
    Zhao, Sizheng S.
    Austin, Philip
    Ibarburu, Gema H.
    Malik, Rayaz A.
    Alam, Uazman
    DIABETOLOGIA, 2023, 66 (10) : 1869 - 1881
  • [33] SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
    Matthew Anson
    Sizheng S. Zhao
    Philip Austin
    Gema H. Ibarburu
    Rayaz A. Malik
    Uazman Alam
    Diabetologia, 2023, 66 : 1869 - 1881
  • [34] Gestione degli effetti collaterali delle terapie con SGLT2i e GLP1 RA
    Luigi Bonifazi Meffe
    Silvia Migliaccio
    Nicola Napoli
    Giuseppe Defeudis
    L'Endocrinologo, 2024, 25 (4) : 452 - 455
  • [35] Eligibility and Utilization of SGLT2i and GLP1-RA in T2D by Cardiovascular and Renal Indications
    Blood, Alexander
    Chang, Lee-Shing
    Colling, Caitlin A.
    Gabovitch, Daniel
    Hamersky, Carol M.
    Durden, Emily
    Holt, Cassie
    Noone, Joshua
    Cannon, Christopher P.
    Wexler, Deborah J.
    Scirica, Benjamin M.
    Waterman, Fanta
    Stern, Gretchen
    Zelle, David
    DIABETES, 2022, 71
  • [36] Trends in prognosis and use of SGLT2i and GLP-1 RA in patients with diabetes and coronary artery disease
    Ritsinger, Viveca
    Avander, Kamila
    Lagerqvist, Bo
    Lundman, Pia
    Norhammar, Anna
    CARDIOVASCULAR DIABETOLOGY, 2024, 23 (01)
  • [37] Initiation of SGLT2i vs GLP1-RA and incidence of AKI in persons with type 2 diabetes mellitus
    Jensen, Simon Kok
    Heide-Jorgensen, Uffe
    Andersen, Ina Trolle
    Thomsen, Reimar
    Christiansen, Christian Fynbo
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [38] Initiation of SGLT2i vs GLP1-RA and incidence of AKI in persons with type 2 diabetes mellitus
    Jensen, Simon Kok
    Heide-Jorgensen, Uffe
    Andersen, Ina Trolle
    Thomsen, Reimar
    Christiansen, Christian Fynbo
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I197 - I198
  • [39] The Difference in the Effects on Microalbuminuria Depending on the Order of GLP-1RA and SGLT2i Therapy in Type 2 Diabetes
    Ohara, Masaya
    Motoyama, Koka
    Tamai, Anna
    Sakura, Takeshi
    Yakushiji, Yosuke
    Hosoi, Masayuki
    DIABETES, 2019, 68
  • [40] Risk of Urogenital Infections in Patients with Type 2 Diabetes Initiating SGLT2i Versus GLP-1RA: A Danish Emulated Target Trial
    Ljungberg, Christine
    Kristensen, Frederik P. B.
    Dalager-Pedersen, Michael
    Vandenbroucke-Grauls, Christina
    Norgaard, Mette
    Thomsen, Reimar W. W.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 46 - 46
12345